Pivotal bioVenture Partners has held the closing of Pivotal bioVenture Partners Fund I, raising over USD300 million to invest in early stage biotechnology companies.
Pivotal bioVenture Partners, funded by the Nan Fung Group, is led by Dr Tracy Saxton and Vincent Cheung.
Pivotal’s investment strategy is centred on identifying companies developing groundbreaking, differentiated science from discovery to early clinical development with the potential to deliver transformative therapies.
“This is an amazing period of innovation in medicine as our knowledge of life sciences is constantly evolving,” says Saxton. “Pivotal will invest in biotechnology companies with strong teams and differentiated science that can be mined to develop therapeutics to improve human health. There are many funds focused on de-risked clinical assets rather than early stage therapeutics, however, we plan to be an active investor in the early stage arena and look forward to partnering with leading-edge, science-based companies to achieve this goal.”
